Informações:
Falhas:
ID
13640
Descrição
Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities; ODM derived from: https://clinicaltrials.gov/show/NCT00001568
Link
https://clinicaltrials.gov/show/NCT00001568
Palavras-chave
Versões (1)
- 22/02/2016 22/02/2016 -
Transferido a
22 de fevereiro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Colorectal Neoplasm NCT00001568
Eligibility Colorectal Neoplasm NCT00001568
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Neoplasm NCT00001568
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
cea levels
Item
rising serum cea levels greater than 6 on two successive tests.
boolean
C0201933 (UMLS CUI [1])
Surgery, residual or recurrent disease, criteria for study groups
Item
resectable residual or recurrent disease. patients in the occult arm (arm 1) must have no visible residual disease in the abdomen at the time of the last surgical exploration. in addition, there must be no imageable definitive site of recurrent disease using conventional imaging modalities including; ct scan of chest/ abdomen/ pelvis with contrast, mri scan, and chest x-ray. patients in arm 2 may have a single site of recurrent or metastatic disease which is resectable but in whom additional sites of disease are not known and no imageable disease other than a solitary site of potentially resectable disease is identified.
boolean
C0038894 (UMLS CUI [1])
C0543478 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
C0027627 (UMLS CUI [4])
C0543478 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
C0027627 (UMLS CUI [4])
ecog performance status
Item
patients must have an ecog performance status of 0-1.
boolean
C1520224 (UMLS CUI [1])
return to nih for follow-up
Item
patients must be willing to return to nih for follow-up.
boolean
C1321605 (UMLS CUI [1])
informed consent
Item
patients must be able to provide informed consent as demonstrated by the signed consent.
boolean
C0021430 (UMLS CUI [1])
surgery
Item
patients must be 2 or more months from abdominal or thoracic surgery.
boolean
C0038894 (UMLS CUI [1])
abdominal exploration
Item
no patients with medical contraindication to abdominal exploration.
boolean
C0085704 (UMLS CUI [1])
recurrent disease, metastatic disease outside of the abdominal cavity, body weight
Item
no patients with recurrent disease detected by conventional imaging studies as outlined above. metastatic disease localized outside of the abdominal cavity by conventional imaging studies as outlined above. patients must weigh less than 136 kgs. which is the weight limit for the scanner tables.
boolean
C0277556 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
C0005910 (UMLS CUI [3])
C0027627 (UMLS CUI [2])
C0005910 (UMLS CUI [3])
prior murine monoclonal antibodies, hama test will be performed
Item
no patients with previous injection of murine monoclonal antibodies: human anti-mouse assay (hama) will be performed in patients with prior history of receiving murine monoclonal antibodies.
boolean
C2916903 (UMLS CUI [1])
C1868744 (UMLS CUI [2])
C1868744 (UMLS CUI [2])
pregnant or breast feeding
Item
no patients that are pregnant or breast feeding.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
hiv
Item
patients who are hiv + will be excluded.
boolean
C0019682 (UMLS CUI [1])